April 20, 2020 10:02 AM EDTUpdated 10:22 AM

Sofinnova Telethon Fund backs Naldini's gene therapy biotech; ORIC prices $75M IPO

ENDPOINTS

→ The Sofinnova Telethon Fund has found a new gene therapy upstart to back. The fund selected Genespire for its portfolio, tapping a biotech inspired …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sofinnova Telethon Fund backs Naldini's gene therapy biotech; ORIC prices $75M IPO

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sofinno­va Telethon Fund backs Nal­dini's gene ther­a­py biotech; ORIC prices $75M IPO

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sofinnova Telethon Fund backs Naldini's gene therapy biotech; ORIC prices $75M IPO